Xiaofei Liang

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1783684/publications.pdf

Version: 2024-02-01

25 papers	744 citations	516710 16 h-index	580821 25 g-index
25 all docs	25 docs citations	25 times ranked	1484 citing authors

#	Article	IF	Citations
1	Adaptive Responses of Pseudomonas aeruginosa to Treatment with Antibiotics. Antimicrobial Agents and Chemotherapy, 2022, 66, AAC0087821.	3.2	7
2	Nanocrystal-loaded liposome for targeted delivery of poorly water-soluble antitumor drugs with high drug loading and stability towards efficient cancer therapy. International Journal of Pharmaceutics, 2021, 599, 120418.	5.2	23
3	Discovery of IHMT-EZH2-115 as a Potent and Selective Enhancer of Zeste Homolog 2 (EZH2) Inhibitor for the Treatment of B-Cell Lymphomas. Journal of Medicinal Chemistry, 2021, 64, 15170-15188.	6.4	12
4	Degradation of Components of the Lpt Transenvelope Machinery Reveals LPS-Dependent Lpt Complex Stability in Escherichia coli. Frontiers in Molecular Biosciences, 2021, 8, 758228.	3.5	6
5	Discovery of 6â€²-chloro-N-methyl-5â€™-(phenylsulfonamido)-[3,3â€²-bipyridine]-5-carboxamide (CHMFL-PI4K-127) as a novel Plasmodium falciparum PI(4)K inhibitor with potent antimalarial activity against both blood and liver stages of Plasmodium. European Journal of Medicinal Chemistry, 2020, 188, 112012.	5.5	13
6	Discovery of (S)-2-(1-(4-Amino-3-(3-fluoro-4-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)propyl)-3-cyclopropyl-5-fluoroquin (IHMT-PI3KÎ´-372) as a Potent and Selective PI3KÎ´ Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease. Journal of Medicinal Chemistry, 2020, 63, 13973-13993.	6.4	12
7	An ultra-long circulating nanoparticle for reviving a highly selective BCR-ABL inhibitor in long-term effective and safe treatment of chronic myeloid leukemia. Nanomedicine: Nanotechnology, Biology, and Medicine, 2020, 29, 102283.	3.3	1
8	Discovery of N-(4-(6-Acetamidopyrimidin-4-yloxy)phenyl)-2-(2-(trifluoromethyl)phenyl)acetamide (CHMFL-FLT3-335) as a Potent FMS-like Tyrosine Kinase 3 Internal Tandem Duplication (FLT3-ITD) Mutant Selective Inhibitor for Acute Myeloid Leukemia. Journal of Medicinal Chemistry, 2019, 62, 875-892.	6.4	20
9	Lipid A Has Significance for Optimal Growth of Coxiella burnetii in Macrophage-Like THP-1 Cells and to a Lesser Extent in Axenic Media and Non-phagocytic Cells. Frontiers in Cellular and Infection Microbiology, 2018, 8, 192.	3.9	51
10	Discovery of (S)-2-amino-N-(5-(6-chloro-5-(3-methylphenylsulfonamido)pyridin-3-yl)-4-methylthiazol-2-yl)-3-methylbutanamide (CHMFL-PI3KD-317) as a potent and selective phosphoinositide 3-kinase delta (PI3KÎ´) inhibitor. European Journal of Medicinal Chemistry, 2018, 156, 831-846.	5.5	8
11	Discovery of 2-((3-Acrylamido-4-methylphenyl)amino)-N-(2-methyl-5-(3,4,5-trimethoxybenzamido)phenyl)-4-(methylamino)pyrimidine-5-carbox (CHMFL-BMX-078) as a Highly Potent and Selective Type II Irreversible Bone Marrow Kinase in the X Chromosome (BMX) Kinase Inhibitor. Journal of Medicinal Chemistry, 2017, 60, 1793-1816.	6.4	17
12	Curative Treatment of Severe Gram-Negative Bacterial Infections by a New Class of Antibiotics Targeting LpxC. MBio, 2017, 8, .	4.1	24
13	Ammonia Induces Autophagy through Dopamine Receptor D3 and MTOR. PLoS ONE, 2016, 11, e0153526.	2.5	24
14	A Scalable Synthesis of the Difluoromethyl-allo-threonyl Hydroxamate-Based LpxC Inhibitor LPC-058. Journal of Organic Chemistry, 2016, 81, 4393-4398.	3.2	14
15	Drug design from the cryptic inhibitor envelope. Nature Communications, 2016, 7, 10638.	12.8	50
16	High susceptibility of MDR and XDR Gram-negative pathogens to biphenyl-diacetylene-based difluoromethyl-allo-threonyl-hydroxamate LpxC inhibitors. Journal of Antimicrobial Chemotherapy, 2016, 71, 2874-2882.	3.0	25
17	Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxam (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Leukemia. Journal of Medicinal Chemistry, 2016, 59, 1984-2004.	6.4	17
18	Simultaneous inhibition of Vps34 kinase would enhance PI3KÎ´ inhibitor cytotoxicity in the B-cell malignancies. Oncotarget, 2016, 7, 53515-53525.	1.8	19

#	Article	IF	Citations
19	Characterization of selective and potent PI3KÎ´ inhibitor (PI3KD-IN-015) for B-Cell malignances. Oncotarget, 2016, 7, 32641-32651.	1.8	7
20	Structural Basis of the Promiscuous Inhibitor Susceptibility of Escherichia coli LpxC. ACS Chemical Biology, 2014, 9, 237-246.	3.4	29
21	Synthesis, Structure, and Antibiotic Activity of Aryl-Substituted LpxC Inhibitors. Journal of Medicinal Chemistry, 2013, 56, 6954-6966.	6.4	67
22	Storage of Hydrogen Spin Polarization in Long-Lived ¹³C₂ Singlet Order and Implications for Hyperpolarized Magnetic Resonance Imaging. Journal of the American Chemical Society, 2013, 135, 9632-9635.	13.7	65
23	Species-Specific and Inhibitor-Dependent Conformations of LpxC: Implications for Antibiotic Design. Chemistry and Biology, 2011, 18, 38-47.	6.0	110
24	Syntheses, structures and antibiotic activities of LpxC inhibitors based on the diacetylene scaffold. Bioorganic and Medicinal Chemistry, 2011, 19, 852-860.	3.0	81
25	Lipooligosaccharide is required for the generation of infectious elementary bodies in Chlamydia trachomatis. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 10284-10289.	7.1	42